Context Therapeutics: Undervalued Cancer Fighter
Source: SeekingAlpha
2025-06-10 07:10:43 ET
Context Therapeutics ( CNTX ) is a clinical stage biotechnology company developing treatments for solid cancerous tumors using novel Bispecific T-cell engaging (BS-TCE or B-TCE or BiTE) technologies. Considerable work has been undertaken in the BS-TCE arena, providing some confidence Context's development work is properly focused....
Read the full article on Seeking Alpha
For further details see:
Context Therapeutics: Undervalued Cancer Fighter
Context Therapeutics Inc.
NASDAQ: CNTX
CNTX Trading
-0.34% G/L:
$2.945 Last:
122,729 Volume:
$2.88 Open:
CNTX Latest News
December 16, 2025 12:18:00 pm
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
November 07, 2025 07:30:00 am
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 05, 2025 04:15:57 pm
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
CNTX Stock Data
$216,834,858
38,589,254
2.16%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Philadelphia
